GlassScriptPhysician profile
Anna C Landry
NPI 1639348394
$4,924.60
in general payments reported to CMS, 2019-2025
29 companies · $970 in 2025
The $970 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $1,107 · 2023: $1,322 · 2024: $1,007 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $966.64 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $727.95 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $685.68 | 2021-2025 | Leqvio |
| Abbott Laboratories | $307.93 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boston Scientific Corporation | $237.10 | 2021-2025 | Watchman Flx, Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.96 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $207.62 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $195.16 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $183.89 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $162.84 | 2023-2025 | Wegovy, Ozempic |
| Amgen INC. | $160.53 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $149.36 | 2022-2025 | Farxiga |
| Amarin Pharma, INC. | $98.10 | 2021-2022 | |
| Heartflow, INC. | $98.09 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $72.58 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $61.43 | 2025 | Evkeeza |
| Silk Road Medical, INC. | $49.64 | 2021-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Alnylam Pharmaceuticals INC. | $47.70 | 2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.81 | 2021-2022 | |
| Scpharmaceuticals INC. | $35.56 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $35.17 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $34.89 | 2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $29.50 | 2023 | Optimizer |
| Recor Medical INC | $24.44 | 2024 | Paradise Renal Denervation System |
| Sanofi-Aventis U.S. LLC | $22.71 | 2022 | |
| Celgene Corporation | $19.70 | 2022 | |
| Abiomed | $19.30 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $16.77 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.